Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Kennedy Concannon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Pyridones, Pyrazoles, Itraconazole, Heart Transplantation. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Mayo Midwest Pharmacy Research Committee.
Abstract (Originalsprache)
Itraconazole and posaconazole are frequently prescribed following transplantation to prevent and treat fungal infections. Navigating drug interactions is challenging due to these agents’ potent CYP3A4 inhibition, and literature describing concurrent apixaban, a CYP3A4 substrate, is limited. This retrospective study of cardiothoracic transplant recipients evaluates the impact of itraconazole and posaconazole on apixaban exposure and reports clinical outcomes from routine apixaban dose reduction. Institutional practice reduces apixaban to 2.5 mg twice daily with itraconazole or posaconazole and obtains apixaban therapeutic drug monitoring (TDM), expected range 34–230 ng/mL. Eighteen levels collected in 15 patients on itraconazole displayed a median [IQR] apixaban trough of 143 ng/mL [95–195]. Fifteen levels collected in 13 patients on posaconazole displayed a median [IQR] apixaban trough of 124 ng/mL [93–174]. Two major bleed events, three VTE, two stroke, and eight instances of clot resolution were identified. Reduced‐dose apixaban resulted in apixaban exposure similar to normal dosing in the general population. Apixaban TDM is encouraged for individualized dosing when administered with itraconazole and posaconazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic Hospital, Rochester, Minnesota, USA.
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic Hospital, Rochester, Minnesota, USA.
- Division of Cardiovascular Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA.
ORCID-Profile: Kennedy Concannon, Rachel Huntsman, Kristin Cole, Cassie Kennedy, Andrew Rosenbaum, Adley Lemke
Förderung
- Mayo Midwest Pharmacy Research Committee
Zitieren
APA
Concannon, K., Huntsman, R., Cole, K., Kennedy, C., Rosenbaum, A., & Lemke, A. (2025). Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70165
Vancouver
Concannon K, Huntsman R, Cole K, Kennedy C, Rosenbaum A, Lemke A. Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70165
BibTeX
@article{Concannon2025,
author = {Concannon, Kennedy and Huntsman, Rachel and Cole, Kristin and Kennedy, Cassie and Rosenbaum, Andrew and Lemke, Adley},
title = {Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70165}
}
EUVIMED